Related Experiment Video
Updated: May 8, 2026
07:38
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study
Laura Dos1, Sandra Pujadas, Montserrat Estruch
1Integrated Adult Congenital Heart Disease Unit of Vall d'Hebron University Hospital and Santa Creu i Sant Pau University Hospital, Barcelona, Spain; Autonomous University of Barcelona, Spain.
International Journal of Cardiology
|August 27, 2013
Summary
Eplerenone treatment in patients with a failing systemic right ventricle (SRV) showed a trend toward reducing collagen turnover biomarkers, suggesting potential for treating myocardial fibrosis.
Area of Science:
- Cardiology
- Pharmacology
- Biomarkers
Background:
- No established pharmacological treatments exist for failing systemic right ventricle (SRV).
- Myocardial fibrosis is implicated in the pathophysiology of SRV.
Purpose of the Study:
- To evaluate the effects of eplerenone on cardiac parameters and collagen turnover biomarkers in patients with SRV.
- To assess eplerenone's potential in managing myocardial fibrosis in SRV.
Main Methods:
- A 12-month, double-blind, placebo-controlled clinical trial.
- Assessed SRV mass, ejection fraction, neurohormonal levels, and collagen turnover biomarkers (CTBs) using cardiac MRI.
- Included 26 patients with SRV post-atrial switch repair and 14 healthy controls.
Main Results:
- Patients with SRV exhibited elevated levels of NT-proBNP, CICP, and ICTP compared to controls.
- Eplerenone treatment showed a trend towards reducing CICP, NT-proMMP1, TIMP1, and galectin 3, with a lower increase in ICTP.
- Eplerenone did not conclusively reduce SRV mass or improve SRV function.
Conclusions:
- Eplerenone improved the altered collagen turnover biomarker profile in SRV patients.
- Reduction of myocardial fibrosis may represent a viable therapeutic target for SRV.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...